Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”
- Authors: Breder V.V.1, Zhukova L.G.2, Bolotina L.V.3, Demidova I.A.4, Zhulikov Y.A.1, Lubennikova E.V.1, Naskhletashvili D.R.1, Orlov S.V.5, Orlova R.V.6,7, Romanov I.S.1, Savelov N.A.4, Sarantseva K.A.1, Tyulyandina A.S.1, Fedyanin M.Y.1,8,9
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- Loginov Moscow Clinical Scientific Center
- Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
- Moscow City Oncology Hospital №62
- Pavlov First Saint Petersburg State Medical University
- Saint Petersburg State University
- City Oncology Center
- Moscow Multidisciplinary Clinical Center “Kommunarka”
- Pirogov National Medical and Surgical Center
- Issue: Vol 25, No 3 (2023)
- Pages: 295-300
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/148893
- DOI: https://doi.org/10.26442/18151434.2023.3.202441
- ID: 148893
Cite item
Full Text
Abstract
NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tumors and discuses clinical data on the efficacy and safety of entrectinib.
Full Text
##article.viewOnOriginalSite##About the authors
Valeriy V. Breder
Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: vbreder@yandex.ru
ORCID iD: 0000-0002-6244-4294
d. sci. (med.)
Russian Federation, MoscowLiudmila G. Zhukova
Loginov Moscow Clinical Scientific Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4848-6938
d. sci. (med.), prof. RAS
Russian Federation, MoscowLarisa V. Bolotina
Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4879-2687
d. sci. (med.)
Russian Federation, MoscowIrina A. Demidova
Moscow City Oncology Hospital №62
Email: editor@omnidoctor.ru
cand. sci. (med.)
Russian Federation, MoscowYaroslav A. Zhulikov
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4108-439X
oncologist
Russian Federation, MoscowElena V. Lubennikova
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-5289-7866
cand. sci. (med.)
Russian Federation, MoscowDavid R. Naskhletashvili
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4218-9652
cand. sci. (med.)
Russian Federation, MoscowSergey V. Orlov
Pavlov First Saint Petersburg State Medical University
Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-6080-8042
d. sci. (med.), prof., corr. member RAS
Russian Federation, Saint PetersburgRashida V. Orlova
Saint Petersburg State University; City Oncology Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4447-9458
d. sci. (med.), prof.
Russian Federation, Saint PetersburgIlya S. Romanov
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-5421-5985
d. sci. (med.)
Russian Federation, MoscowNikita A. Savelov
Moscow City Oncology Hospital №62
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4164-2240
pathologist
Russian Federation, MoscowKsenia A. Sarantseva
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-7817-8429
cand. sci. (med.)
Russian Federation, MoscowAlexandra S. Tyulyandina
Blokhin National Medical Research Center of Oncology
Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-6104-7473
d. sci. (med.)
Russian Federation, MoscowMikhail Yu. Fedyanin
Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center
Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-5615-7806
d. sci. (med.)
Russian Federation, MoscowReferences
- Demetri GD. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022;28(7):1302-12.
- Fischer H. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-Oncology. 2020;22(6):819-29.
- Krzakowski M. Updated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. J Clin Oncol. 2022;40(16_suppl.):3099.
- Lozano-Ortega G. Tumour-specific randomized controlled trials in rare oncogene-driven cancers: asking for the impossible. Personalized & Precision Medicine – Methodological & Statistical Research. 2019;22(3):838-9.
- Krebs MG. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):1-9.
- Doebele RC. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021;10(17):1271-82.
- Krebs MG, Blay JY, Le Tourneau C, et al. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):1-9.
- Brogaart N. Health technology assessment challenges associated with tumour-agnostic therapies: learnings from the assessments of entrectinib and larotrectinib. OHE Consulting Report, London: Office of Health Economics, 2021.
- Bowles D. Entrectinib in patients with NTRK fusion-positive (NTRK-fp) thyroid cancer: Updated data from startrk-2. Endocrine Abstracts, 2022.
- Goto K. An updated analysis of the clinical efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) sarcoma. Japanese Orthopaedic Association – 54th Annual Musculoskeletal Tumor Meeting, 2021.
- Ogale S, Zerbini CEH, Antoniou M, Freund R. A response to "The potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of trk fusionpositive metastatic lung cancer. J Manag Care Spec Pharm. 2020;26(12):1616-7.
- Lu S. Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC). ESMO-Asia. 2022:264P.
- Murakami H. Entrectinib in Japanese patients with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours. ESMO-ASIA. 2022:390P.
- Murphy P. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess. 2021;25(76).
- Hechtman JF. NTRK insights: best practices for pathologists. Modern Pathol. 2022;35:298-305.
- Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127-40.
- Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417-27.
- Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32.
- Sohal D, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38(27):3217-30.
- Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-505.
- Haddad RD, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(8):925-51.
- Yoshino T, Pentheroudakis G, Mishima S, et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020;31(7):861-72.
- Conde E, Hernandez S, Sanchez E, et al. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Arch Pathol Lab Med. 2021;145(8):1031-40.
- Siozopoulou V, Smits E, De Winne K, et al. NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel). 2021;11(3):478.
- Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rew Clin Oncol. 2022;19(5):328-41.